title: Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma.
abstract: BACKGROUND
  Aromatase inhibitors may affect lipid metabolism, inflammatory response and antioxidant balance.
  
  
  METHODS
  One hundred and eighty-six post-menopausal patients with breast carcinoma underwent evaluation of parameters of lipid metabolism, inflammatory response and antioxidant balance immediately before as well as 2 and 4 months after the start of therapy with aromatase inhibitors.
  
  
  RESULTS
  A significant increase in total, very low density lipoprotein (VLDL) and low density lipoprotein (LDL) cholesterol, lipoprotein (a), retinol, C-reactive protein and fibrinogen was observed. The changes of serum lipid concentrations were restricted mostly to the patients pre-treated with tamoxifen who had significantly lower baseline levels of these parameters.
  
  
  CONCLUSIONS
  An increase of serum cholesterol, lipoprotein (a), C-reactive protein and fibrinogen in patients treated with aromatase inhibitors is the result of tamoxifen withdrawal rather than a direct effect of therapy. No significant changes in serum lipids were observed in patients treated with aromatase inhibitors in the first-line setting.
authors: Department of Oncology, Palacký University Medical School & Teaching Hospital, I.P. Pavlova 6, 77520 Olomouc, Czech Republic. bohuslav.melichar@fnol.cz
authors: Bohuslav
authors: B
authors: Melichar
authors: Hana
authors: H
authors: Kalábová
authors: Lenka
authors: L
authors: Krcmová
authors: Lubor
authors: L
authors: Urbánek
authors: Radomír
authors: R
authors: Hyspler
authors: Dagmar
authors: D
authors: Solichová
authors: Karolina
authors: K
authors: Melicharová
authors: Miroslav
authors: M
authors: Pecka
authors: Zdenek
authors: Z
authors: Zadák
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D047072:Aromatase Inhibitors / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D002097:C-Reactive Protein / Q000378:metabolism*; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D017270:Lipoprotein(a) / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008079:Lipoproteins, VLDL / Q000378:metabolism*; D019798:Neopterin / Q000652:urine*; D011379:Prognosis; D011446:Prospective Studies; D013629:Tamoxifen / Q000494:pharmacology; D014801:Vitamin A / Q000097:blood; D024502:alpha-Tocopherol / Q000097:blood*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D017270:Lipoprotein(a); D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D013629:Tamoxifen; D014801:Vitamin A; D019798:Neopterin; D005340:Fibrinogen; D002097:C-Reactive Protein; D024502:alpha-Tocopherol